CD155 promotes the progression of colorectal cancer by restraining CD8+ T cells via the PI3K/AKT/NF-κB pathway by Rongpu Liang, Liting Liu, Dongbing Ding, Yiquan Li, Jiannan Ren, Bo Wei

“…CD155 may become an important prognostic biomarker and an effective target for colorectal cancer immunotherapy.…”
Get full text

Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Mela... by Mengqi Zhang, Lulu Wang, Wan Liu, Tian Wang, Francesco De Sanctis, Lifang Zhu, Guizhong Zhang, Jian Cheng, Qin Cao, Jingying Zhou, Aldo Tagliabue, Vincenzo Bronte, Dehong Yan, Xianchun Wan, Guang Yu

“…These findings indicate that ART controls the functional polarization of MDSCs and targeting MDSCs by ART provides a novel therapeutic strategy to enhance anti-PD-L1 cancer immunotherapy.…”
Get full text

Akkermansia muciniphila Enhances the Antitumor Effect of Cisplatin in Lewis Lung Cancer Mice by Zhuo Chen, Xiang Qian, Shasha Chen, Xiaoxuan Fu, Guanjun Ma, Aiqin Zhang

“…Recently, intestinal flora plays a vital role in the occurrence and development of tumors and there is link between cancer immunotherapy and Akkermansia muciniphila (Akk). However, the therapeutic efficacy of Akk in lung cancer remained unclear. …”
Get full text

PD-1 suppresses human CD38+ circulating Tfr cells and regulates humoral immunity by Heng Zhang, Hui Zheng, Lin Guo, Ying Tong, Xiaolu Ma, Yanchun Wang, Renquan Lu, Cuncun Chen, Suhong Xie

“…However, the impact of anti-PD-1 therapy on host humoral immunity in humans during cancer immunotherapy requires further investigation.Methods We evaluated immunoglobulin titers by ELISA and screened the immune landscape of immune cells from 25 healthy donors and 50 cases including 25 new-onset hepatocellular carcinoma (HCC) patients prior to systemic treatment and 25 HCC patients undergoing anti-PD-1 therapy by multicolor flow cytometry. …”
Get full text

Translating Unconventional T Cells and Their Roles in Leukemia Antitumor Immunity by Nilberto Dias de Araújo, Fábio Magalhães Gama, Mateus de Souza Barros, Thaís Lohana Pereira Ribeiro, Fabíola Silva Alves, Lilyane Amorim Xabregas, Andréa Monteiro Tarragô, Adriana Malheiro, Allyson Guimarães Costa

“…Collectively, these T cell populations can recognize lipid antigens, specially modified peptides and small molecule metabolites, in addition to having several other advantages, which can provide more effective applications in cancer immunotherapy. In recent years, these cell populations have been associated with a repertoire of anti- or protumor responses and play important roles in the dynamics of solid tumors and hematological malignancies, thus, encouraging the development of new investigations in the area. …”
Get full text

Comparative efficacy and safety of first-line neoadjuvant therapy for early-stage non-small cell lung cancer based on immune checkpoint inhibitor therapy: a systematic review and n... by Linfeng Wang, Guangda Zheng, Yue Hu, Ayidana Maolan, Yue Luo, Yue Li, Rui Liu

Get full text

Antitumor effects of natural killer cells derived from gene-engineered human-induced pluripotent stem cells on hepatocellular carcinoma by Mayuna Nakamura, Yuka Tanaka, Keishi Hakoda, Masahiro Ohira, Tsuyoshi Kobayashi, Kenji Kurachi, Kouichi Tamura, Hideki Ohdan

“…Recently, cell-based immunotherapy using natural killer (NK) cells has attracted considerable attention in cancer immunotherapy. NK cells generated from induced pluripotent stem cells (iPSCs) are a new option for use as an NK cell resource. …”
Get full text

Immune checkpoint inhibitors in cancer patients with autoimmune disease: Safety and efficacy by Jiayuan Le, Yuming Sun, Guangtong Deng, Yating Dian, Yanli Xie, Furong Zeng

“…The utilization of immune-checkpoint inhibitors (ICIs) in cancer immunotherapy frequently leads to the occurrence of immune-related adverse events (irAEs), making it generally not recommended for patients with preexisting autoimmune diseases. …”
Get full text

Novel protein-based prognostic signature linked to immunotherapeutic efficiency in ovarian cancer by Shuo-Fu Chen, Liang-Yun Wang, Yi-Sian Lin, Cho-Yi Chen

Get full text

Neo-BCV: A Novel Bacterial Liquid Complex Vaccine for Enhancing Dendritic Cell-Mediated Immune Responses Against Lung Cancer by Zilong Zhu, Zhuze Chu, Fei Fei, Chenxi Wu, Zhengyue Fei, Yuxia Sun, Yun Chen, Peihua Lu

“…Conclusions: These findings highlight Neo-BCV’s potential as a safe and effective therapeutic strategy, offering a novel avenue for clinical translation in lung cancer immunotherapy.…”
Get full text

Lactylation-driven TNFR2 expression in regulatory T cells promotes the progression of malignant pleural effusion by Yao Liu, Qiong Zhou, Siyu Zhang, Wenbei Peng, Haolei Wang, Xuan Xiang, Linlin Ye, Xiaoshan Wei, Zihao Wang, Qianqian Xue

“…Background Although tumor necrosis factor receptor 2 (TNFR2) has been recognized as an attractive next-generation candidate target for cancer immunotherapy, the factors that regulate the gene expression and their mechanistic effects on tumor-infiltrating regulatory T cells (Treg cells) remain poorly understood.Methods Single-cell RNA sequencing analysis was employed to analyze the phenotypic and functional differences between TNFR2+ Treg cells and TNFR2− Treg cells. …”
Get full text

Identification of signaling networks associated with lactate modulation of macrophages and dendritic cells by Rapeepat Sangsuwan, Bhasirie Thuamsang, Noah Pacifici, Phum Tachachartvanich, Devan Murphy, Abhineet Ram, John Albeck, Jamal S. Lewis

“…The advancement in the understanding of cancer immune evasion has manifested the development of cancer immunotherapeutic approaches such as checkpoint inhibitors and interleukin agonists. Although cancer immunotherapy breakthroughs have demonstrated improved potency for cancer treatment, only a fraction of patients effectively respond to these treatments. …”
Get full text

A high-valence bismuth(V) nanoplatform triggers cancer cell death and anti-tumor immune responses with exogenous excitation-free endogenous H2O2- and O2-independent ROS generation by Yizhang Tang, Xujiang Yu, Liangrui He, Meng Tang, Wenji Yue, Ruitong Chen, Jie Zhao, Qi Pan, Wanwan Li

“…Overall, this work offers a nanomedicine based on high-valence bismuth(V) nanoplatform and underscores its great potential for cancer immunotherapy.…”
Get full text

PLGA confers upon conventional nonfluorescent molecules luminescent properties to trigger 1O2-induced pyroptosis and immune response in tumors by Lan Zou, Rujing Wang, Mengnan Zhao, Yuke Li, Chen Sun, Jinjin Xie, Yan Chen, Qian Jing, Dandan Mi, Sanjun Shi

“…Abstract Pyroptosis, a recently identified cellular demise regulated by gasdermin family proteins, is emerging as a promising avenue in cancer immunotherapy. However, the realm of light-controlled pyroptosis in cancer cells remains largely unexplored. …”
Get full text

Systemic therapy of skin metastatic melanoma with BRAF gene mutation by Yu. S. Shakh-Paronyants, S. V. Cheporov, N. P. Shiryaev, A. V. Ukgarskiy, P. V. Nesterov, N. S. Korzina

“…In the second group of patients, stabilization was noted in 39.6 % of patients, partial response in 25.6 % of patients, complete response was absent.Conclusion. The use of cancer immunotherapy drugs in the first line of treatment in patients with metastatic melanoma of the skin and the presence of BRAF mutation in the short term is not inferior in effectiveness to the use of targeted drugs, and in the medium and long term exceeds targeted drugs.…”
Get full text

Plant-nanoparticles enhance anti-PD-L1 efficacy by shaping human commensal microbiota metabolites by Yun Teng, Chao Luo, Xiaolan Qiu, Jingyao Mu, Mukesh K. Sriwastva, Qingbo Xu, Minmin Liu, Xin Hu, Fangyi Xu, Lifeng Zhang, Juw Won Park, Jae Yeon Hwang, Maiying Kong, Zhanxu Liu, Xiang Zhang, Raobo Xu, Jun Yan, Michael L. Merchant, Craig J. McClain, Huang-Ge Zhang

“…Here we investigate the impact of plant-derived nanoparticles (PNP) on gut microbiota and metabolites in context of cancer immunotherapy with the humanized gnotobiotic mouse model. …”
Get full text

MicroRNA-3145 as a potential therapeutic target for hepatitis B virus: inhibition of viral replication via downregulation of HBS and HBX by Amrizal Muchtar, Amrizal Muchtar, Daichi Onomura, Daichi Onomura, Dan Ding, Dan Ding, Hironori Nishitsuji, Kunitada Shimotohno, Shunpei Okada, Keiji Ueda, Koichi Watashi, Takaji Wakita, Kei Iida, Kei Iida, Hironori Yoshiyama, Hisashi Iizasa

Get full text

The impact of CD3ζ ITAM multiplicity and sequence on CAR T-cell survival and function by Shubhabrata Majumdar, Hilda Echelibe, Maria Bettini, Matthew L. Bettini

“…IntroductionChimeric antigen receptor (CAR) expressing T-cells have shown great promise for the future of cancer immunotherapy with the recent clinical successes achieved in treating different hematologic cancers. …”
Get full text

CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma by Dan Zhu, Haralambos Hadjivassiliou, Catherine Jennings, David Mikolon, Massimo Ammirante, Sharmistha Acharya, Jon Lloyd, Mahan Abbasian, Rama Krishna Narla, Joseph R. Piccotti, Katie Stamp, Ho Cho, Kandasamy Hariharan

“…The CD47-SIRPα axis has become an important target for cancer immunotherapy. To date, the advancement of CD47-targeted modalities is hindered by the ubiquitous expression of the target, often leading to rapid drug elimination and hematologic toxicity including anemia. …”
Get full text

Pan-cancer characterization of m6A-mediated regulation of T cell exhaustion dynamics and clinical relevancies in human cancers by Weiping Ji, Ye Fang, Liwei Chen, Yitong Zheng, Yifei Pei, Changqiu Mei, Meng Zhou

“…Our findings provide novel insights into the role of m6A in TEX regulation and underscore the potential of m6A regulators as biomarkers and therapeutic targets for advancing cancer immunotherapy.…”
Get full text